Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker

References

• Atmaca A, Gedik O. 2006. Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes. Adv Ther. 23:615–622.
   PubMed Web of Science ®Google Scholar
• Aubert G, Burnier M, Dulloo A, Perregaux C, Mazzolai L, Pralong F, Zanchi A. 2010. Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain. Metabolism. 59:25–32.
   PubMed Web of Science ®Google Scholar
• Bregonzio C, Seltzer A, Armando I, Pavel J, Saavedra JM. 2008. Angiotensin II AT(1) receptor blockade selectively enhances brain AT(2) receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. Stress. 11:457–466.
   PubMed Web of Science ®Google Scholar
• Changmin H, Jianguo C, Dongming L, Guohong L, Mingxing D. 2010. Effects of xylazole alone and in combination with ketamine on the metabolic and neurohumoral responses in healthy dogs. Vet Anaesth Analg. 4:322–328.
   Google Scholar
• Comfere T, Sprung J, Kumar MM, Draper M, Wilson DP, Williams BA, Danielson DR, Liedl L, Warner DO. 2005. Angiotensin system inhibitors in a general surgical population. Anesth Analg. 100:636–644.
   PubMed Web of Science ®Google Scholar
• De Cavanagh EM, Toblli JE, Ferder L, Piotrkowski B, Stella I, Fraga CG, Inserra F. 2005. Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats. Cell Mol Biol. 51:573–578.
   PubMed Web of Science ®Google Scholar
• Ecelbarger CM, Rash A, Sinha RK, Tiwari S. 2010. The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat. Mediators Inflamm. 2010:1–12.
   Web of Science ®Google Scholar
• Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. 2006. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol. 45:154–162.
   PubMed Web of Science ®Google Scholar
• Feng X, Luo Z, Ma L, Ma S, Yang D, Zhao Z, Yan Z, He H, Cao T, Liu D, Zhu Z. 2011. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. J Cell Mol Med. 15:1572–1581.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Nakamura T, Kataoka K, Nako H, Tokutomi Y, Dong YF, Ogawa H, Kim-Mitsuyama S. 2010. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. J Hypertens. 28:340–352.
   PubMed Web of Science ®Google Scholar
• Gaillet S, Lachuer J, Malaval F, Assenmacher I, Szafarczyk A. 1991. The involvement of noradrenergic ascending pathways in the stress-induced activation of ACTH and corticosterone secretions is dependent on the nature of stressors. Exp Brain Res. 87:173–180.
   PubMed Web of Science ®Google Scholar
• Gibson A, Hart SL, Patel S. 1986. Effects of 6-hydroxydopamine-induced lesions of the paraventricular nucleus, and of prazosin, on the corticosterone response to restraint in rats. Neuropharmacology. 25:257–260.
   PubMed Web of Science ®Google Scholar
• Gilliam-Davis S, Payne VS, Kasper SO, Tommasi EN, Robbins ME, Diz DI. 2007. Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. Am J Physiol Heart Circ Physiol. 293:H1327–H1333.
   Web of Science ®Google Scholar
• Gohlke P, Kox T, Jurgensen T, von KS, Rascher W, Unger T, Culman J. 2002. Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats. Naunyn Schmiedebergs Arch Pharmacol. 365:477–483.
   PubMed Web of Science ®Google Scholar
• Hardie DG, Carling D. 1997. The AMP-activated protein kinase—fuel gauge of the mammalian cell?. Eur J Biochem. 246:259–273.
   PubMedGoogle Scholar
• Hardie DG, Hawley SA, Scott JW. 2006. AMP-activated protein kinase—development of the energy sensor concept. J.Physiol (Lond). 574:7–15.
   Google Scholar
• Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG. 2003. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol. 2:28.1–28.16.
   Google Scholar
• Jones ES, Black MJ, Widdop RE. 2004. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol. 37:1023–1030.
   PubMed Web of Science ®Google Scholar
• Kahn BB, Alquier T, Carling D, Hardie DG. 2005. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1:15–25.
   PubMed Web of Science ®Google Scholar
• Kola B. 2008. Role of AMP-activated protein kinase in the control of appetite. J Neuroendocrinol. 20:942–951.
   PubMed Web of Science ®Google Scholar
• Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, Korbonits M. 2005. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem. 280:25196–25201.
   PubMed Web of Science ®Google Scholar
• Kola B, Grossman AB, Korbonits M. 2008. The role of AMP-activated protein kinase in obesity. Front Horm Res. 36:198–211.
   PubMed Web of Science ®Google Scholar
• Leong DS, Terron JA, Falcon-Neri A, Armando I, Ito T, Johren O, Tonelli LH, Hoe KL, Saavedra JM. 2002. Restraint stress modulates brain, pituitary and adrenal expression of angiotensin II AT(1A), AT(1B) and AT(2) receptors. Neuroendocrinology. 75:227–240.
   PubMed Web of Science ®Google Scholar
• Liu H, Kitazato KT, Uno M, Yagi K, Kanematsu Y, Tamura T, Tada Y, Kinouchi T, Nagahiro S. 2008. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: In-vivo and in-vitro studies. J Hypertens. 26:1435–1445.
   PubMed Web of Science ®Google Scholar
• Li M, Zhao J, Hu Y, Lu H, Guo J. 2009. Oxygen free radicals regulate energy metabolism via AMPK pathway following cerebral ischemia. Neurol Res. 32:779–784.
   PubMed Web of Science ®Google Scholar
• Machado LJ, Marubayashi U, Reis AM, Coimbra CC. 1998. The hyperglycemia induced by angiotensin II in rats is mediated by AT1 receptors. Braz J Med Biol Res. 31:1349–1352.
   PubMed Web of Science ®Google Scholar
• McBride A, Hardie DG. 2009. AMP-activated protein kinase—a sensor of glycogen as well as AMP and ATP?. Acta Physiol (Oxf). 196:99–113.
   PubMed Web of Science ®Google Scholar
• Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB. 2004. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 428:569–574.
   PubMed Web of Science ®Google Scholar
• Muller-Fielitz H, Markert A, Wittmershaus C, Pahlke F, Johren O, Raasch W. 2011. Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. Naunyn Schmiedebergs Arch Pharmacol. 383:373–384.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Ito T, Hoe K, Saavedra JM. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res. 2000a; 871:29–38.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000b; 31:2478–2486.
   PubMed Web of Science ®Google Scholar
• Pacak K. 2000. Stressor-specific activation of the hypothalamic–pituitary–adrenocortical axis. Physiol Res. 49 Suppl 1: S11–S17.
   PubMed Web of Science ®Google Scholar
• Palkovits M, Baffi JS, Pacak K. 1997. Stress-induced fos-like immunoreactivity in the pons and the medulla oblongata of rats. Stress. 1:155–168.
   PubMedGoogle Scholar
• Pavel J, Benicky J, Murakami Y, Sanchez-Lemus E, Saavedra JM. 2008. Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann NY Acad Sci. 1148:360–366.
   PubMed Web of Science ®Google Scholar
• Pavlatou MG, Mastorakos G, Lekakis I, Liatis S, Vamvakou G, Zoumakis E, Papassotiriou I, Rabavilas AD, Katsilambros N, Chrousos GP. 2008. Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: Preliminary results. Stress. 11:62–72.
   PubMed Web of Science ®Google Scholar
• Pelisch N, Hosomi N, Ueno M, Masugata H, Murao K, Hitomi H, Nakano D, Kobori H, Nishiyama A, Kohno M. 2010. Systemic candesartan reduces brain angiotensin II via downregulation of brain renin–angiotensin system. Hypertens Res. 33:161–164.
   PubMed Web of Science ®Google Scholar
• Ramamurthy S, Ronnett GV. 2006. Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J Physiol (Lond). 574:85–93.
   Google Scholar
• Reis FM, Ribeiro-de-Oliveira AJr, Guerra RM, Reis AM, Coimbra CC. 1996. Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress. Life Sci. 58:155–161.
   PubMed Web of Science ®Google Scholar
• Ribeiro-de-Oliveira AJr, Guerra RM, Foscolo RB, Marubayashi U, Reis AM, Coimbra CC. 1999. Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats. J Endocrinol. 162:237–242.
   PubMed Web of Science ®Google Scholar
• Ribeiro-de-Oliveira A, Guerra RM, Foscolo RB, Marubayashi U, Reis AM, Coimbra CC. 2001. Bromocriptine-induced dissociation of hyperglycemia and prolactin response to restraint. Pharmacol Biochem Behav. 68:229–233.
   PubMed Web of Science ®Google Scholar
• Ribeiro-Oliveira AJr, Nogueira AI, Pereira RM, Boas WW, dos Santos RA, Simoes E, Silva AC. 2008. The renin–angiotensin system and diabetes: An update. Vasc Health Risk Manag. 4:787–803.
   PubMedGoogle Scholar
• Ronnett GV, Ramamurthy S, Kleman AM, Landree LE, Aja S. 2009. AMPK in the brain: Its roles in energy balance and neuroprotection. J Neurochem. 109 Suppl 1: 17–23.
   PubMed Web of Science ®Google Scholar
• Saavedra JM, Benicky J. 2007. Brain and peripheral angiotensin II play a major role in stress. Stress. 10:185–193.
   PubMed Web of Science ®Google Scholar
• Unger T. 2003. Inhibiting angiotensin receptors in the brain: Possible therapeutic implications. Curr Med Res Opin. 19:449–451.
   PubMed Web of Science ®Google Scholar
• Yamada F, Inoue S, Saitoh T, Tanaka K, Satoh S, Takamura Y. 1993. Glucoregulatory hormones in the immobilization stress-induced increase of plasma glucose in fasted and fed rats. Endocrinology. 132:2199–2205.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kadowaki T. 2008. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 32 Suppl 7: S13–S18.
   PubMed Web of Science ®Google Scholar
• Yoshida D, Higashiura K, Shinshi Y, Satoh K, Hyakkoku M, Yoshida H, Miyazaki Y, Ura N, Shimamoto K. 2009. Effects of angiotensin II receptor blockade on glucose metabolism via AMP-activated protein kinase in insulin-resistant hypertensive rats. J Am Soc Hypertens. 3:3–8.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie Z, Dong Y, Wang S. 2008. Liu C and Zou MH Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem. 283:27452–27461.
   PubMed Web of Science ®Google Scholar
• Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM. 2006. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol. 552:112–122.
   PubMed Web of Science ®Google Scholar